MEDX ... anybody following? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following?

MEDX 31.15

-0.3%

Nov 3 1:15 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: LJM who wrote (1976)	4/16/2008 5:03:56 PM
From: Icebrg	of 2240

Not bad considering what they once paid for the drug: Located in Bloomsbury, N.J., Celldex said that it will acquire substantially all assets of Alteris in exchange for 1.2 million shares of Celldex Common Stock, $1.5 million in cash and certain potential milestone and other payments. Through this acquisition of Alteris, Celldex will obtain exclusive rights to ALT-110, a therapeutic cancer vaccine currently in a Phase II clinical trial for the treatment of brain cancer and a Phase I clinical trial for the treatment of prostate, gastric, non-small cell lung and ovarian cancers. ALT-110 is based on a variant of the epidermal growth factor receptor known as EGFRvIII. In addition, Celldex will acquire several patent applications covering the Rapid Identification of Alternative Splicing (RIAS), a proprietary technology platform for the discovery of new disease-specific targets.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next